[SCHEDULE 13G/A] Actinium Pharmaceuticals, Inc SEC Filing

Rhea-AI Filing Summary

The Vanguard Group has filed Amendment No. 1 to Schedule 13G for Actinium Pharmaceuticals (ATNM), triggered by the 30 June 2025 reportable event. The filing discloses 1,371,840 ATNM common shares beneficially owned, equal to 4.39 % of the outstanding class, placing Vanguard below the 5 % threshold noted in Item 5.

According to Item 4, Vanguard holds no voting power—sole or shared—but retains dispositive authority over nearly all of the shares (sole: 1,362,947; shared: 8,893). Vanguard is filing in its capacity as an investment adviser (Rule 13d-1(b)(1)(ii)(E)); the ownership is on behalf of its advisory clients, none of which individually own more than 5 %. Certification in Item 10 confirms the stake is held in the ordinary course of business and not for the purpose of influencing control of ATNM.

Insights

Institutional Ownership Analyst

TL;DR — Vanguard declares a passive 4.39 % ATNM stake; below 5 % level, implying neutral impact.

Vanguard’s 13G/A shows it controls 1.37 M Actinium shares but has no voting rights, underscoring a purely fiduciary holding for client accounts. Dropping (or remaining) below 5 % removes heightened reporting duties and suggests limited intent to influence management. The absence of voting power further supports a passive posture. For investors, the filing signals continued, albeit modest, institutional support without activist implications. Market impact should be limited unless accompanied by future buying or selling disclosures.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Actinium Pharmaceuticals Inc

(Name of Issuer)

Common Stock

(Title of Class of Securities)

00507W206

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 00507W206

1

Names of Reporting Persons

The Vanguard Group

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

PENNSYLVANIA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,362,947.00
8	Shared Dispositive Power 8,893.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,371,840.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.39 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Actinium Pharmaceuticals Inc
(b)	Address of issuer's principal executive offices: 100 Park Avenue, 23rd Floor, New York, NY, 10017
Item 2.
(a)	Name of person filing: The Vanguard Group
(b)	Address or principal business office or, if none, residence: 100 Vanguard Blvd., Malvern, PA 19355
(c)	Citizenship: PA
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 00507W206
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 1371840
(b)	Percent of class: 4.39 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 1362947
	(iv) Shared power to dispose or to direct the disposition of: 8893
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5%.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

The Vanguard Group

Signature:	Ashley Grim
Name/Title:	Head of Global Fund Administration
Date:	07/29/2025

FAQ

How many Actinium Pharmaceuticals (ATNM) shares does Vanguard currently own?

Vanguard reports 1,371,840 ATNM common shares beneficially owned.

What percentage of ATNM’s outstanding shares does Vanguard hold?

The filing lists a holding of 4.39 % of the common stock class.

Does Vanguard have voting power over its ATNM shares?

No. Item 4 states 0 shares with sole or shared voting power.

Why was this Schedule 13G/A filed?

It updates Vanguard’s passive ownership position as an investment adviser under Rule 13d-1(b) for the 30 Jun 2025 event.

What is Actinium Pharmaceuticals’ CUSIP number mentioned in the filing?

The CUSIP number disclosed is 00507W206.

When was the certification signed and by whom?

It was signed on 29 July 2025 by Ashley Grim, Head of Global Fund Administration.